Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nuwellis, Inc. stock logo
CHFS
Nuwellis
$0.25
$4.79
$4.86
$37.50
$1.50M1.55467,323 shs2.29 million shs
Digirad Co. stock logo
DRAD
Digirad
$0.90
$3.58
$1.99
$8.84
$4.28M0.18485,592 shs13,298 shs
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
$5.67
$3.42
$12.72
$54.38M2.55132,982 shs36,800 shs
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
$0.30
+3.0%
$0.57
$0.22
$2.79
$3.31M1.13153,585 shs54,193 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nuwellis, Inc. stock logo
CHFS
Nuwellis
-1.63%+45.15%-32.02%-47.76%-91.04%
Digirad Co. stock logo
DRAD
Digirad
-0.45%+0.01%+0.57%-5.30%+6.46%
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
0.00%0.00%0.00%0.00%0.00%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
-2.01%-9.20%-20.81%-73.12%-79.07%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/AN/AN/AN/AN/AN/AN/AN/A
Digirad Co. stock logo
DRAD
Digirad
N/AN/AN/AN/AN/AN/AN/AN/A
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
N/AN/AN/AN/AN/AN/AN/AN/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/AN/AN/AN/A
Digirad Co. stock logo
DRAD
Digirad
N/AN/AN/AN/A
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
N/AN/AN/AN/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Nuwellis, Inc. stock logo
CHFS
Nuwellis
$5.51M0.27N/AN/A$12.79 per share0.02
Digirad Co. stock logo
DRAD
Digirad
$114.18M0.04$1.30 per share0.69$10.30 per share0.09
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
$3.38M0.00N/AN/A$4.80 per share0.00
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/A$0.67 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Nuwellis, Inc. stock logo
CHFS
Nuwellis
-$18.11M-$279.28N/AN/AN/A-254.26%-173.61%-131.01%N/A
Digirad Co. stock logo
DRAD
Digirad
-$4.63M-$0.35N/AN/A-5.32%-3.75%-0.85%N/A
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
-$8.92MN/A0.00N/AN/AN/A-13.58%-13.02%N/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
-$10.06M-$1.93N/AN/AN/A-197.36%-144.22%5/14/2024 (Confirmed)

Latest NDRA, EYES, DRAD, and CHFS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2024N/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/AN/AN/A
3/28/2024Q4 2023
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/A-$0.17-$0.17-$0.17N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/AN/AN/AN/AN/A
Digirad Co. stock logo
DRAD
Digirad
$2.20244.42%N/AN/A N/A
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
N/AN/AN/AN/AN/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/A
6.87
5.97
Digirad Co. stock logo
DRAD
Digirad
0.88
1.27
0.91
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
N/A
22.15
22.15
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/A
6.26
3.36

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Nuwellis, Inc. stock logo
CHFS
Nuwellis
65.06%
Digirad Co. stock logo
DRAD
Digirad
11.38%
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
N/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
1.19%

Insider Ownership

CompanyInsider Ownership
Nuwellis, Inc. stock logo
CHFS
Nuwellis
0.60%
Digirad Co. stock logo
DRAD
Digirad
12.49%
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
47.20%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
4.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Nuwellis, Inc. stock logo
CHFS
Nuwellis
666.04 millionN/ANot Optionable
Digirad Co. stock logo
DRAD
Digirad
6184.76 millionN/ANot Optionable
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
1513.14 million6.94 millionOptionable
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
2111.04 million10.51 millionNot Optionable

NDRA, EYES, DRAD, and CHFS Headlines

Recent News About These Companies

ENDRA Life Sciences (NDRA) to Release Quarterly Earnings on Tuesday
ENDRA Life Sciences Inc Registered Shs
Life sciences push brings new partner to Orrick
Survey: Life Sciences Incubators Anticipate Continued Growth

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Nuwellis logo

Nuwellis

NASDAQ:CHFS
Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
Digirad logo

Digirad

NASDAQ:DRAD
Digirad Corporation provides healthcare solutions in the United States and internationally. It operates through five segments: Diagnostic Services, Diagnostic Imaging, Mobile Healthcare, Building and Construction, and Real Estate and Investments. The company offers imaging and monitoring services to healthcare providers; and contract diagnostic imaging, including computerized tomography (CT), magnetic resonance imaging, positron emission tomography (PET), PET/CT, and nuclear medicine and healthcare services to hospitals, integrated delivery networks, and federal institutions on a long-term contract basis, as well as provisional services to institutions that are in transition. It also develops, sells, and maintains solid-state gamma cameras, such as nuclear cardiac imaging systems and general purpose nuclear imaging systems to physician offices and hospitals; and offers camera maintenance contract services. In addition, it manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; and manages real estate assets and investments. Digirad Corporation was founded in 1985 and is headquartered in Suwanee, Georgia.
Second Sight Medical Products logo

Second Sight Medical Products

NASDAQ:EYES
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.
ENDRA Life Sciences logo

ENDRA Life Sciences

NASDAQ:NDRA
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.